Risk of developing As there are more cases of 1.52 $8,397.38 16.2370 $8,119.40 16.2131 –$277.98 –0.0239 $11,660 $8,464 diabetes undiagnosed diabetes in the complications in intervention, if risk of undiagnosed diabetes complications decreases, the incremental (base-case: 1.72) improves. However, this is outweighed by the increased incremental cost due to more complications: favours the comparator - 1.92 $8,447.18 16.2314 $8,318.07 16.1910 –$129.11 –0.0404 $3,196 - Decreased incremental costs outweigh the decrease in incremental effectiveness: favours the intervention Annual cost of $1,836 $7,354.70 16.2340 $7,026.42 16.2015 –$328.28 –0.0326 $10,084 $7,897 As there are more cases of diabetes (with diabetes with complications in complications) the intervention arm, incremental costs decrease: (base-case: $2,648) favours the intervention - $3,459 $9,490.74 16.2340 $9,419.53 16.2015 –$71.21 –0.0326 $2,187 - Increased incremental costs: favours the comparator Eff. = effectiveness; HbA1c = glycated haemoglobin; ICER = incremental cost-effectiveness; NGT = normal glucose tolerance
Risk of developing diabetes complications in undiagnosed diabetes (base-case: 1.72) 1.52 $8,397.38 16.2370 $8,119.40 16.2131 –$277.98 –0.0239 $11,660 $8,464 As there are more cases of undiagnosed diabetes in the intervention, if risk of complications decreases, the incremental improves. However, this is outweighed by the increased incremental cost due to more complications: favours the comparator - 1.92 $8,447.18 16.2314 $8,318.07 16.1910 –$129.11 –0.0404 $3,196 - Decreased incremental costs outweigh the decrease in incremental effectiveness: favours the intervention Annual cost of diabetes (with complications) (base-case: $2,648) $1,836 $7,354.70 16.2340 $7,026.42 16.2015 –$328.28 –0.0326 $10,084 $7,897 As there are more cases of diabetes with complications in the intervention arm, incremental costs decrease: favours the intervention - $3,459 $9,490.74 16.2340 $9,419.53 16.2015 –$71.21 –0.0326 $2,187 - Increased incremental costs: favours the comparator Eff. = effectiveness; HbA1c = glycated haemoglobin; ICER = incremental cost-effectiveness; NGT = normal glucose tolerance
1267-FinalContractedAssessmentReport-accessible.DOCX